Resource Center › Compliance
U.S. State and Local Aggregate Spend Reporting Requirements
See which U.S. states, cities and counties require aggregate spend reporting, what they collect and when reports are due.
10 states, cities and counties
Life Sciences manufacturers
Payments, transfers of value and samples to HCPs and HCOs
Nevada, March 1
Overview
As part of the continued effort to further expand transparency into the financial relationships between Healthcare Professionals (HCPs) and Healthcare Organizations (HCOs) and medical product manufacturers, various cities, counties and states (also known as “jurisdictions”) have enacted legislation that requires the disclosure of data related to these relationships. Depending on the jurisdiction’s requirements, Life Sciences companies must report certain interactions, payments, transfers of value and/or product samples provided to HCPs and HCOs. These jurisdictions also have different reporting deadlines. For more information on a specific jurisdiction’s aggregate spend requirements, see its official source below.
| Jurisdiction | Reporting Deadline | Official Source |
|---|---|---|
| Nevada | March 1 | Nevada |
| Oregon | April 1 | Oregon |
| Vermont | April 1 | Vermont |
| Minnesota | May 1 | Minnesota |
| Connecticut | July 1 | Connecticut |
| District of Columbia | July 1 | D.C. |
| Miami-Dade County (FL) | July 1 | Miami-Dade County |
| Massachusetts | July 1 | Massachusetts |
| Chicago (IL) | No later than 30 days after the department requests it | Chicago |
| California | Company-defined deadline | California |
Pharmaceutical manufacturers must report on payments made to HCPs and HCOs for travel, research, gifts, speaking engagements, meals, entertainment, education and other purposes. Additionally, some jurisdictions require reporting on product samples, vouchers and coupons provided to HCPs. In some instances, pharmaceutical manufacturers must register with the jurisdiction or inform them that a report will be submitted, collect data for the specified reporting period related to these expenditures, format the data according to jurisdictional requirements and submit the report by that jurisdiction’s deadline.
How MedPro Systems Can Help
We help Life Sciences and Healthcare companies drive better health outcomes by reducing complexity across their compliance and commercial operations. With tailored data, solutions and service, our dedicated team of industry veterans simplifies each step and helps customers move forward with confidence and precision.
Our end-to-end global platform, MedPro Compliance Reporting ID®, is the single solution that equips you for the growing complexity and evolving nature of transparency obligations around the world.
Streamline your state and local aggregate spend data capture and reporting with holistic, scalable, integrated transparency coverage enhanced by trusted data and a responsive, proactive team of industry veterans.
FAQ
Frequently Asked Questions
Global Transparency Guide
Navigating Global Transparency Compliance
Download MedPro’s comprehensive guide to global transparency compliance. Learn how leading Life Sciences organizations achieve end-to-end coverage across U.S. and international disclosure obligations in a single platform.
Related resources
-
Provider Verification Beyond Compounding Pharmacy Onboarding
How current provider and facility information supports documented decisions from account setup through order fulfillment.
-
Where Prescriber Verification Fits in the Specialty Pharmacy Workflow
A practical look at verification checkpoints from prescription intake through dispensing and the value of current provider data at each stage.
-
7 Workflow Gaps That Slow Down Life Sciences Compliance Teams
As compliance responsibilities grow, small gaps between data, systems and teams can create extra manual work. Here are 7 places to look first and practical steps your team can take to strengthen the workflow.
-
Two International Disclosure Dates to Plan For
Colombia’s biannual value-transfer filing is due September 30, and Japan’s annual disclosure window follows each company’s fiscal year end.
